What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline

Any nod from the FDA is good news for a company, but some investors might be wondering why the Palforzia approval has stirred up so much excitement. From both medical and financial perspectives, the opportunity is significant. Clearly, with the lack of approved treatments prior to Palforzia, therapy for peanut allergy was an unmet need. And as the following statistics show, it's not a small niche market.